---
schema_version: "secwatch.filing_event.v1"
accession: "0001326190-26-000049"
form_type: "8-K"
ticker: "ALT"
cik: "0001326190"
company_name: "Altimmune, Inc."
filed_at: "2026-08-12T11:33:59+00:00"
generated_at: "2026-08-12T11:35:06.014115+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Altimmune Q2 net loss $22.8M; initiates Phase 3 MASH trial, positive AUD data

## Summary
- Net loss $22.8M ($0.12/share) vs $22.1M ($0.27/share) in Q2 2025; R&D $18.7M, G&A $7.6M.
- Cash and investments $519M as of June 30, 2026; gross proceeds $225M from April 2026 offering.
- Initiated global PERFORMA Phase 3 MASH trial; 52-week data expected 2029; pemvidutide granted FDA Breakthrough Therapy.
- Positive topline RECLAIM Phase 2 AUD: significant reduction in heavy drinking days; Fast Track designation.
- Completed enrollment in RESTORE Phase 2 ALD trial; topline data expected H2 2027.

## SEC filing metadata
- accession: 0001326190-26-000049
- form_type: 8-K
- ticker: ALT
- cik: 0001326190
- company_name: Altimmune, Inc.
- filed_at: 2026-08-12T11:33:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326190/000132619026000049/0001326190-26-000049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326190/000132619026000049/alt-20260812x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326190-26-000049
- JSON: https://secwatch.observer/filing/0001326190-26-000049.json
- Plain text: https://secwatch.observer/filing/0001326190-26-000049.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.